成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Welcome to chemicalbook!
+1 (818) 612-2111
Inquriy
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

RFQ
skype
MY Account
Top
Postion:Product Catalog >Biochemical Engineering>Inhibitors>Metabolism>PPAR agonists>GW0742
GW0742
  • GW0742

GW0742 NEW

Price $43 $68 $127
Package 5mg 10mg 25mg
Min. Order:
Supply Ability: 10g
Update Time: 2024-11-19

Product Details

Product Name: GW0742 CAS No.: 317318-84-6
Purity: 99.85% Supply Ability: 10g
Release date: 2024/11/19

Product Introduction

Bioactivity

NameGW0742
DescriptionGW0742 (GW610742) is an effective and specific PPARδ agonist (EC50: 1 nM/1.1 μM/2 μM, for human PPARδ/α/γ).
Cell ResearchN/TERT-1 keratinocytes are seeded onto 6-well tissue culture dishes at 3×104 cells per well in Ker-SFM. Twenty-four hours later, cell number is measured with a Z1 coulter particle counter to determine plating efficiency (Day 0). For the remaining cells, medium is changed to Ker-SFM/DF-K, and cells are treated in triplicate with 0.1% DMSO, 0.1 μM or 1 μM GW0742. Cell number is determined at daily intervals, and the remaining cells are retreated with fresh media and treatment each day for up to 6 days.(Only for Reference)
In vitroGW0742 shows activity aganist hPPARα, hPPARγ and hPPARδ with EC50 of 1.1 μM, 2 μM and 1 nM, respectively, in cell based transactivation assay. [1] GW0742 (0.2 μM and 1 μM) significant increases in reporter activity of PPARβ/δ in N/TERT-1 keratinocytes. GW0742 (1 μM) results in significant inhibition in the average number of N/TERT-1 keratinocytes. GW0742 (1 μM) results in an increase in the number of cells in the G1 phase and a decrease in the number of cells in the S phase. GW0742 (1 μM) causes a significant increase in the mRNA encoding ADRP, a known PPARβ/δ target gene, in N/TERT-1 keratinocytes as well as mouse primary keratinocytes. GW0742 (1 μM) results in significantly reduced phosphorylation of retinoblastoma (Rb) and a significantly lower level of p42/44 ERK in N/TERT-1 cells. GW0742 (1 μM) leads to an increase in the mRNA encoding a number of known markers of terminal differentiation including TG-I, SPR1A, K10 and involucrin. [2] GW0742 at 100 μM produces a significant reduction in low-KCl-induced neuronal cell death in cerebellar granule neurons. GW0742 at 100 μM induces a pronounced increase in cell death as measured by LDH release after 48 hr of incubation. GW0742 at 100 μM produces a pronounced increase in c-Jun expression at 6 hours in cerebellar granule neuron cultures. GW0742 at 100 μM increases PPARα-mediated transactivation dependent on the presence of 1.5% BSA in MCF-7 cells. [3]
In vivoGW0742-treatment (0.3 mg/Kg, 10 % DMSO, i.p.) has therapeutic effects on pulmonary damage, decreasing many inflammatory and apoptotic parameters detected by measurement of 1) cytokine production; 2) leukocyte accumulation, indirectly measured as decrease of myeloperoxidase (MPO) activity; 3) IkBα degradation and NF-kB nuclear translocation; 4) ERK phosphorylation; 5) stress oxidative by NO formation due to iNOS expression; 6) nitrotyrosine and PAR localization; 7) the degree of apoptosis, evaluated by Bax and Bcl-2 balance, FAS ligand expression and TUNEL staining. Taken together, GW0742 reduces the lung injury and inflammation due to the intratracheal BLEO--instillation in mice.
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
Solubility InformationDMSO : 60 mg/mL (127.26 mM)
Keywordsinhibit | GW 610742 | Inhibitor | PPAR | GW 0742 | GW0742 | Peroxisome proliferator-activated receptors | GW-0742 | GW-610742
Inhibitors RelatedPHYTOL | (S)-(+)-Ibuprofen | BADGE | Cinnamyl alcohol | Daidzein | Fenofibrate | Pioglitazone hydrochloride | 5-Aminosalicylic Acid | Naringenin | Fisetin | 2,3-Butanediol | Icariin
Related Compound LibrariesNuclear Receptor Compound Library | DNA Damage & Repair Compound Library | Anti-Pancreatic Cancer Compound Library | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | NO PAINS Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Preclinical Compound Library | Anti-Cancer Active Compound Library

Company Profile Introduction

Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers. TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.

You may like

Recommended supplier

Product name Price   Suppliers Update time
$1.00/1g
VIP6Y
Shanghai Longyu Biotechnology Co., Ltd.
2024-11-23
$50.00/10g
VIP1Y
hebei hongtan Biotechnology Co., Ltd
2024-06-05
$32.00/1Box
zhuzhou dingcheng meihei comestic co.,ltd
2024-05-29
$0.00/25kg
VIP1Y
Hebei Mojin Biotechnology Co.,Ltd
2024-05-16
$1.00/1g
VIP4Y
Dorne Chemical Technology co. LTD
2024-03-26
$10.00/1kg
VIP1Y
Wuhan Xinhao Biotechnology Co., Ltd
2024-02-23
$30.00/100g
VIP1Y
Sigma Audley
2024-01-29
$0.00/1kg
VIP1Y
Shandong Hanjiang Chemical Co., Ltd
2024-01-25
$30.00/1KG
VIP1Y
Wuhan Ruichi Technology Co., Ltd
2024-01-04
$10.00/1mg
Nantong Guangyuan Chemicl Co,Ltd
2023-11-30
  • Since: 2011-01-07
  • Address: 36?Washington?Street, Wellesley?Hills
INQUIRY